Risk stratification of patients diagnosed with gastrointestinal stromal tumor

Human Pathology

Volumn 39, Issue 10, 2008, Pages 1411-1419

  Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Adjuvant therapy; Gastrointestinal stromal tumors; NIH consensus classification system; Risk stratification

Indexed keywords

ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL TUMOR; ESOPHAGUS TUMOR; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; PROGNOSIS; RECTUM TUMOR; RECURRENT DISEASE; RISK ASSESSMENT; SMALL INTESTINE TUMOR; STOMACH TUMOR; STROMA CELL; TUMOR VOLUME;

CONSENSUS DEVELOPMENT CONFERENCES, NIH AS TOPIC; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MITOSIS; NATIONAL INSTITUTES OF HEALTH (U.S.); PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL RATE; UNITED STATES;

EID: 50649085726     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.06.025     Document Type: Article

References (37)

1. Mucciarini C., Rossi G., Bertolini F., et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 7 (2007) 230
2. Nilsson B., Bumming P., Meis-Kindblom J.M., et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer 103 (2005) 821-829
3. Steigen S.E., and Eide R.J. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS 114 (2006) 192-200
4. Demetri G.D., Benjamin R.S., Blanke C.D., et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 5 Suppl 2 (2007) S1-S29 quiz S30
5. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 (2002) 459-465
6. Buchdunger E., Cioffi C.L., Law N., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295 (2000) 139-145
7. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 (2008) 620-625
8. DeMatteo R.P., Antonescu C.R., Chadaram V., et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup phase II trial ACOSOG Z9000 [ASCO abstract 9009]. J Clin Oncol 23 (2005) 818s
9. DeMatteo R.P., Owzar K., Maki R., et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001 [ASCO abstract 10079]. Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1-5 (2007)
10. Agaimy A., Wunsch P.H., Hofstaedter F., et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 31 (2007) 113-120
11. Kawanowa K., Sakuma Y., Sakurai S., et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 37 (2006) 1527-1535
12. Abraham S.C., Krasinskas A.M., Hofstetter W.L., et al. "Seedling" mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. Am J Surg Pathol 31 (2007) 1629-1635
13. Aparicio T., Boige V., Sabourin J.C., et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 30 (2004) 1098-1103
14. DeMatteo R.P., Gold J.S., Saran L., et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 112 (2008) 608-615
15. DeMatteo R.P., Lewis J.J., Leung D., et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231 (2000) 51-58
16. Fujimoto Y., Nakanishi Y., Yoshimura K., et al. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 6 (2003) 39-48
17. Hsu K.H., Yang T.M., Shan Y.S., et al. Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor. Am J Surg 194 (2007) 148-152
18. Kim T.W., Lee H., Kang Y.K., et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 10 (2004) 3076-3081
19. Koay M.H., Goh Y.W., Iacopetta B., et al. Gastrointestinal stromal tumours (GISTs): a clinicopathological and molecular study of 66 cases. Pathology 37 (2005) 22-31
20. Langer C., Gunawan B., Schuler P., et al. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. Br J Surg 90 (2003) 332-339
21. Martin J., Poveda A., Llombart-Bosch A., et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 23 (2005) 6190-6198
22. Ryu M.H., Kang Y.K., Jang S.J., et al. Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours. Histopathology 51 (2007) 379-389
23. Singer S., Rubin B.P., Lux M.L., et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 20 (2002) 3898-3905
24. Tryggvason G., Gislason H.G., Magnusson M.K., et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 117 (2005) 289-293
25. Wu T.J., Lee L.Y., Yeh C.N., et al. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate. BMC Gastroenterol 6 (2006) 29
26. Gold J.S., Gonen M.I., Maki R.G., et al. A nomogram to predict recurrence after resection of primary gastrointestinal stromal tumor (GIST) [ASCO abstract 55]. Presented at: 2007 Gastrointestinal Cancers Symposium; Orlando, FL; January 19-21 (2007)
27. Takahashi T., Nakajima K., Nishitani A., et al. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol 12 (2007) 369-374
28. Hassan I., You Y.N., Shyyan R., et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol 15 (2008) 52-59
29. Lasota J., vel Dobosz A.J., Wasag B., et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest 87 (2007) 1029-1041
30. Lasota J., Corless C.L., Heinrich M.C., et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol 21 (2008) 476-484
31. Wardelmann E., Buttner R., Merkelbach-Bruse S., et al. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 451 (2007) 743-749
32. Miettinen M., Sobin L.H., and Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29 (2005) 52-68
33. Miettinen M., Makhlouf H., Sobin L.H., et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 30 (2006) 477-489
34. Miettinen M., and Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 23 (2006) 70-83
35. Huang H.Y., Li C.F., Huang W.W., et al. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome. Surgery 141 (2007) 748-756
36. Rutkowski P., Nowecki Z.I., Michej W., et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol 14 (2007) 2018-2027
37. Rutkowski P., Debiec-Rychter M., Nowecki Z.I., et al. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors. Med Sci Monit 13 (2007) CR515-CR522